

United States AMENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/720,952	01/03/2001	Rok Grahek	2260/106	8999
	90 12/11/2001			
Timothy M Murphy Bromberg & Sunstein			EXAMINER	
125 Summer Street			SHAMEEM, GOLAM M	
Boston, MA 02110			ART UNIT	PAPER NUMBER
			1626	
			DATE MAILED: 12/11/2001	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)			
Office Action Summary		09/720,952	GRAHEK ET AL.			
		Examiner	Art Unit			
		Golam M. M. Shameem	1626			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
- Exter after - If the - If NO - Failur - Any r	ORTENED STATUTORY PERIOD FOR MAILING DATE OF THIS COMMUNICAT asions of time may be available under the provisions of 37 sIX (6) MONTHS from the mailing date of this communical period for reply specified above is less than thirty (30) day period for reply is specified above, the maximum statutory re to reply within the set or extended period for reply will, beply received by the Office later than three months after the dipatent term adjustment. See 37 CFR 1.704(b).	FION. CFR 1.136(a). In no event, however, may a retion. Is, a reply within the statutory minimum of thirty period will apply and will expire SIX (6) MON by statute cause the application to become AB.	eply be timely filed y (30) days will be considered timely. THS from the mail of this communication.			
1)🖂	Responsive to communication(s) filed o	n <u>26 January 2001</u> .				
2a)□		This action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-25</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-25</u> is/are rejected.						
7)	Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
—	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)∐ T	11) The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.						
12)☐ The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)⊠ All b)□ Some * c)□ None of:						
	 Certified copies of the priority documents have been received. 					
	2. Certified copies of the priority documents have been received in Application No					
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
2) Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-940 ation Disclosure Statement(s) (PTO-1449) Paper No	8) 5) Notice of Inf	ormal Patent Application (PTO-152)			

Application/Control Number: 09/720,952

Art Unit: 1626

DETAILED ACTION

Status of Claims

Claims 1-25 are pending in this application.

Receipt is acknowledged of the Information disclosure statement filed on 01/26/01.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1 to 25 are rejected under 35 USC § 112 second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The expressions "characterised in", "the use of a", "feeding", "mobile phase" and "is in the lactone form" (should be <u>has a lactone form</u>) place no definite limits or boundaries on the claims. The rejection with respect to "characterized in" and "the use of a" could be overcome by changing it to <u>wherein</u> and <u>using</u> respectively. In claim 1 the plural form "inhibitors" must be changed to the singular form.

Art Unit: 1626

Claim 25 provides for the use of a process, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Claim 25 is rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd.* v. *Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a), which forms the basis for all obviousness rejections, set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or non-obviousness.

Art Unit: 1626

1-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Haytko et al, cited. The difference between the process taught in the reference and the claimed process herein lies merely in the variation of purification technique and conditions for HMG-CoA reductase inhibitor, such as displacement chromatography instead of high performance liquid chromatography (HPLC) which is obvious from the teachings of the prior art absent a showing of unexpected results. The claimed process would have been prima facie obvious to one of ordinary skill in the art at the time of the invention was made since Haytko et al teach the process (yield a product of purity greater than 99.5%, see column 1) which is similar to claimed process but using different purification techniques, the interchange of or substitution one for another would be obvious to one ordinary skill in the art. It is obvious to purify compounds by a similar chromatography technique in the absence of any unobvious or unexpected results. The motivation to use the claimed process derives from the expectation that the use of similar technique such as displacement chromatography under specific set of reaction conditions would have been expected to give similar yields of product. The determination of optimum purification and recovery conditions for a compound is a routine experimentation to one skilled in the art. In looking at the instant claimed process as a whole, it would have been obvious to one skilled in the art unless unobvious or unexpected results can be shown.

Haytko et al; Carta et al and Sibeijn et al are cited to show the state of the art.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Golam Shameem, Ph.D. whose telephone number is (703) 305-0116. The examiner can normally be reached on Monday-Friday from 8:30 AM - 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph

Mckane, can be reached at (703) 308-4537. The Unofficial fax phone number for this Group is

(703) 308-7922. The Official fax phone numbers for this Group are (703) 308-4556 or 305-

3592. When filing a FAX in Technology Center 1600, please indicate in the Header (upper right)

"Official" for papers that are to be entered into the file, and "Unofficial" for draft documents and

other communications with the PTO that are not for entry into the file of the application. This

will expedite processing of your papers.

Communications via Internet e-mail regarding this application, other than those under 35

U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be

addressed to [joseph.mcKane@uspto.gov]. All Internet e-mail communications will be made of

record in the application file. PTO employees will not communicate with applicant via Internet

e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive

data could be identified unless there is of record an express waiver of the confidentiality

requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy

published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG

89.

Any inquiry of a general nature or relating to the status of this application should be

directed to the Group receptionist, whose telephone number is (703) 308-1235.

Golam M M Shameem, Ph.D. Patent Examiner
Art Unit 1626, Group 1620

Technology Center 1

Floyd D. Higel

Primary Patent Examiner Art Unit 1626, Group 1620

Technology Center 1